Raphas Co., Ltd.
Financials
Valuation Metrics
Raphas Co., Ltd.'s Market Cap is ₩672B. At end of 2025 it was ₩1169B. Ranked #1575 of 2,421 in KR market (top 65%), #929 of 1,640 on KOSDAQ (top 57%), #32 of 57 in Household & Personal Products (top 56%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 67.19B KRW | KR#1,575/2,421 Sec#32/57 |
| Revenue | 30.16B KRW | KR#2,031/2,421 Sec#46/57 |
| Net Income | -6.11B KRW | KR—/2,421 Sec—/57 |
| Total Assets | 67.97B KRW | KR#2,037/2,421 Sec#44/57 |
| Net Assets | 27.54B KRW | KR#2,204/2,421 Sec#51/57 |
| Employees | 100 | KR#1,636/2,421 Sec#35/57 |
| Value | ||
| P/B | 2.44x | KR#2,030/2,421 Sec#47/57 |
| P/S | 2.23x | KR#1,870/2,421 Sec#47/57 |
| FCF Yield | 1.23% | KR#1,122/2,421 Sec#31/57 |
| Profitability | ||
| ROE | -22.19% | KR#2,114/2,421 Sec#50/57 |
| ROA | -8.99% | KR#2,078/2,421 Sec#51/57 |
| Op. Margin | -12.98% | KR#2,042/2,421 Sec#49/57 |
| Revenue Growth | 4.55% | KR#1,223/2,421 Sec#32/57 |
| Earnings Growth | -2953.76% | KR#1,345/2,421 Sec#35/57 |
| Financial Health | ||
| Debt Ratio | 146.81% | KR#1,887/2,421 Sec#49/57 |
| Total Debt | 38.04B KRW | KR#1,121/2,421 Sec#22/57 |
| FCF | 828.0M KRW | KR#1,159/2,421 Sec#30/57 |
| Cash | 12.34B KRW | KR#1,564/2,421 Sec#27/57 |
| Current Ratio | 0.77x | KR#1,972/2,421 Sec#43/57 |
| Performance | ||
| 1Y Return | -49.16% | KR#2,042/2,421 Sec#45/57 |
| 1M Return | -9.71% | KR#2,086/2,421 Sec#49/57 |
| From 52W High | -54.83% | KR#1,641/2,421 Sec#42/57 |
| 1Y MDD | -56.22% | KR#1,271/2,421 Sec#38/57 |
| Trading | ||
| Volume | 4,533 shares | KR#2,146/2,421 Sec#48/57 |
| Trading Value | 34.2M KRW | KR#1,974/2,421 Sec#44/57 |
| Foreign Own. | 0.00% | KR—/2,421 Sec—/57 |
| Per Share | ||
| EPS | -685 KRW | KR—/2,421 Sec—/57 |
| BPS | 3,086 KRW | KR#1,842/2,421 Sec#43/57 |
Company Info
Raphas, established in 2006 and headquartered in Gangseo-gu, Seoul, was listed on KOSDAQ as a technology growth company in 2019. It specializes in the research, development, manufacturing, and sales of soluble microneedle patches, a transdermal drug delivery technology. While current sales are primarily in cosmetic fields like beauty patches, the company is expanding its business into pharmaceuticals, vaccine patches, and medical devices. Its unique DEN technology allows for microneedle production in about 5 minutes using only room-temperature air circulation, without UV light, and offers flexible control over length and pattern without molds.